1285 Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial.
https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1
1284 Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.
https://www.pnas.org/content/118/6/e2005191118
1283 Engineered off-the-shelf therapeutic T cells resist host immune rejection.
https://www.nature.com/articles/s41587-020-0601-5
1282 On-demand biomanufacturing of protective conjugate vaccines.
https://advances.sciencemag.org/content/7/6/eabe9444
1281 Local immune response to food antigens drives meal-induced abdominal pain.
https://www.nature.com/articles/s41586-020-03118-2
1280 Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques.
https://www.pnas.org/content/118/5/e2022496118
1279 The immunogenicity of candidate adenovirus vaccine vectors is enhanced by the activation of mucosal-associated invariant T cells.
https://science.sciencemag.org/content/371/6528/521
1278 Human dimeric IgA antibodies are potent neutralizers of SARS-CoV-2.
https://stm.sciencemag.org/content/13/577/eabf1555
1277 Early specific antibody responses against SARS-CoV-2 include IgG, IgM, and IgA, but IgA may neutralize virus and control infection to a larger extent.
https://stm.sciencemag.org/content/13/577/eabd2223
1276 Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity.
https://science.sciencemag.org/content/371/6527/405
|
